

## Letters to the Editor

### First phosphite ligand based on ((4*R*,5*S*)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)- diphenylmethanol

K. N. Gavrilov,<sup>a\*</sup> I. M. Novikov,<sup>a</sup> I. V. Chuchelkin,<sup>a</sup> S. V. Zhiglov,<sup>a</sup> M. S. Levkina,<sup>a</sup> A. N. Volov,<sup>b</sup> and I. A. Zamilatskov<sup>b</sup>

<sup>a</sup>S. A. Esenin Ryazan State University,

46 ul. Svobody, 390000 Ryazan, Russian Federation.


Fax: +7 (491 2) 28 1435. E-mail: k.gavrilov@rsu.edu.ru

<sup>b</sup>A. N. Frumkin Institute of Physical Chemistry and Electrochemistry, Russian Academy of Sciences,

31 Leninsky prosp., 119071 Moscow, Russian Federation.

Fax: +7 (495) 952 0449. E-mail: alex123.87@mail.ru


((4*R*,5*R*)-2,2-Dimethyl-1,3-dioxolan-4,5-diyl)bis-(diphenylmethanol) (TADDOL) is one of the most accessible enantiopure  $C_2$  symmetric diols extensively used as versatile chiral ligand/auxiliary.<sup>1–3</sup> TADDOL-derived phosphites revealed themselves to be efficient chiral ligands for a wide range of metal-catalyzed asymmetric reactions.<sup>3–8</sup> To date, no phosphite derivatives of ((4*R*,5*S*)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)diphenylmethanol (**1**) were described. 1,4-Diol **1**, analog of TADDOL with the pronounced  $C_1$  symmetry, is readily accessible from available monomethyl (*R,R*)-tartrate.<sup>9</sup>



Amidophosphite **2** with P\*-stereocenter was synthesized by treatment of diol **1** with  $PCl_3$  followed by the reaction with pyrrolidine (Scheme 1). In this reaction, pyrrolidine plays a role of both the reagent and the HCl scavenger. Note that the synthesis of compound **2** is fast due also to the intermediate formation of the corresponding chloro-

phosphite in the  $PCl_3$  medium in the presence of catalytic amount of *N*-methylpyrrolidone. Amidophosphite **2** was purified by flash column chromatography; this compound is relatively stable in air and at long-term storage in a dry atmosphere.

Scheme 1




**Reagents and conditions** 1)  $PCl_3$ , *N*-methylpyrrolidone, reflux, 5 min, 2)  $(CH_2)_4NH$ , toluene.

Synthesis of ligand **2** is diastereoselective, the ratio of the epimers at the P\*-stereocenter is 19 : 1. This ratio was

determined from  $^{31}\text{P}$  NMR ( $\text{CDCl}_3$ ) spectra of compound **2** exhibiting two narrow singlets at  $\delta_{\text{P}}$  144.9 (95%) and 137.3 (5%). It should be emphasized that the presence of the  $\text{P}^*$ -stereogenic donor atom in the ligand **2** facilitates the chirality transfer on the key step of the catalytic cycle.<sup>10,11</sup>

Stereodifferentiating ability of amidophosphite **2** was estimated using enantioselective Pd-catalyzed allylic sulfonylation of (*E*)-1,3-diphenylallyl acetate (**3**) (Scheme 2, Table 1) as a model reaction. It is of note that chiral allyl sulfones are of considerable interest for the stereoselective organic synthesis.<sup>11</sup>

Scheme 2



**Reagents and conditions:** 1)  $[\text{Pd}(\text{allyl})\text{Cl}]_2$ , ligand **2**, THF, 20 °C, 15 min, 2) *p*-TolSO<sub>2</sub>Na, 20 °C, 48 h.

As a pre-catalyst,  $[\text{Pd}(\text{allyl})\text{Cl}]_2$  was used. Allylic sulfone (**5**)-**4** was obtained in high yield and high enantioselectivity up to 90% *ee* (see Table 1). In this reaction, the known TADDOL-derived bis-phosphine ligand gives no more than 68% *ee*.<sup>9</sup> Thus, amidophosphite **2** is a promising chiral ligand and its application in asymmetric catalysis is now extensively studied in our research group.

$^{31}\text{P}$ ,  $^1\text{H}$ , and  $^{13}\text{C}$  NMR spectra were run on Bruker Avance 400 (161.98 ( $^{31}\text{P}$ ), 400.13 ( $^1\text{H}$ ), and 100.61 MHz ( $^{13}\text{C}$ )) and Bruker Avance III 600 (242.94 ( $^{31}\text{P}$ ), 600.13 ( $^1\text{H}$ ), and 150.9 MHz ( $^{13}\text{C}$ )) spectrometers relative to 85%  $\text{H}_3\text{PO}_4$  in  $\text{D}_2\text{O}$  ( $^{31}\text{P}$ ) and

$\text{Me}_4\text{Si}$  ( $^1\text{H}$  and  $^{13}\text{C}$ ). The signals in the  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were assigned using COSY, DEPT, and HSQC NMR techniques and taking in account published data.<sup>9</sup> Electron impact mass spectra (EI, 70 eV) were obtained on a Varian MAT-311 instrument. Enantiomeric analyses of the product of allylic sulfonylation were performed on a Stayer HPLC system. For elemental analyses, Carlo Erba EA1108 CHNS-O microanalyzer was used.

All reactions were carried out in anhydrous solvents under dry argon. ((4*R*,5*S*)-5-(Hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)diphenylmethanol (**1**) were synthesized by the known procedure.<sup>9</sup> The starting compounds, (*E*)-1,3-diphenylallyl acetate (**3**) and complex  $[\text{Pd}(\text{allyl})\text{Cl}]_2$ , were synthesized as earlier described.<sup>12</sup> Pd-catalyzed asymmetric allylic sulfonylation of compound **3** with sodium *p*-toluenesulfinate and determination of enantiomeric excesses of product **4** were performed following the published procedures.<sup>13</sup>

Pyrrolidine, *N*-methylpyrrolidone, and sodium *p*-toluenesulfinate are commercially available from Fluka and Aldrich.

**(1*R*,7*S*)-9,9-Dimethyl-2,2-diphenyl-4-(pyrrolidin-1-yl)-3,5,8,10-tetraoxa-4-phosphabicyclo[5.3.0]decane (2).** To a vigorously stirred suspension of compound **1** (0.63 g, 2 mmol) in  $\text{PCl}_3$  (4 mL, 45.5 mmol), *N*-methylpyrrolidone (0.01 g, 0.1 mmol) was added and the mixture was refluxed for 5 min until homogeneity. The  $\text{PCl}_3$  excess was removed *in vacuo* (40 Torr), the residue was dried *in vacuo* (30 min, 1 Torr) to remove the  $\text{PCl}_3$  traces and dissolved in toluene (12 mL). To the obtained solution, pyrrolidine (0.4 mL, 4.8 mmol) was added at 20 °C under vigorous stirring. The reaction mixture was refluxed for 15 min, cooled to 20 °C, and filtered through an alumina pad. The filtrate was concentrated *in vacuo* (40 Torr). Purification of the residue by flash column chromatography (silica gel, elution with  $\text{CH}_2\text{Cl}_2$ ) afforded compound **2** in the yield of 0.59 g (71%), colorless oil. Found (%): C, 67.05; H, 6.76; N, 3.24.  $\text{C}_{23}\text{H}_{28}\text{NO}_4\text{P}$ . Calculated (%): C, 66.82; H, 6.83; N, 3.39.  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ),  $\delta$ : 25.4 (s,  $\text{CH}_3$ ); 25.9 (d,  $\text{CH}_2$ ,  $^3J_{\text{C,P}} = 5.4$  Hz); 27.4 (s,  $\text{CH}_3$ ); 44.5 (d,  $\text{CH}_2\text{N}$ ,  $^2J_{\text{C,P}} = 15.0$  Hz); 65.6 (d, C(6),  $^2J_{\text{C,P}} = 10.0$  Hz); 75.3 (d, C(7),  $^3J_{\text{C,P}} = 3.8$  Hz); 80.6 (d, C(2),  $^2J_{\text{C,P}} = 5.7$  Hz); 86.2 (d, C(1),  $^3J_{\text{C,P}} = 19.1$  Hz); 110.7 (s, C(9)); 126.8 (s,  $\text{CH}_{\text{Ph}}$ ); 126.9 (s,  $\text{CH}_{\text{Ph}}$ ); 127.0 (s,  $\text{CH}_{\text{Ph}}$ ); 127.3 (s,  $\text{CH}_{\text{Ph}}$ ); 128.0 (s,  $\text{CH}_{\text{Ph}}$ ); 128.4 (s,  $\text{CH}_{\text{Ph}}$ ); 141.3 (s,  $\text{C}_{\text{Ph}}$ ); 146.7 (s,  $\text{C}_{\text{Ph}}$ ).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ),  $\delta$ : 0.66 (s, 3 H,  $\text{CH}_3$ ); 1.46 (s, 3 H,  $\text{CH}_3$ ); 1.84–1.91 (m, 4 H,  $\text{CH}_2$ ); 3.24–3.29 (m, 2 H,  $\text{CH}_2\text{N}$ ); 3.39–3.44 (m, 2 H,  $\text{CH}_2\text{N}$ ); 3.89 (ddd, 1 H, C(6)H,  $^2J_{\text{H,H}} = 11.2$  Hz,  $^3J_{\text{H,H}} = 9.2$  Hz,  $^3J_{\text{H,P}} = 2.4$  Hz); 4.18 (td, 1 H, C(7)H,  $^3J_{\text{H,H}} = 9.2$  Hz,  $^3J_{\text{H,H}} = 3.6$  Hz); 4.33 (ddd, 1 H, C(6)H,  $^2J_{\text{H,H}} = 11.2$  Hz,  $^3J_{\text{H,H}} = 3.6$  Hz,  $^3J_{\text{H,P}} = 28.2$  Hz); 4.96 (dd, 1 H, C(1)H,  $^3J_{\text{H,H}} = 9.1$  Hz,  $^4J_{\text{H,P}} = 3.9$  Hz); 7.22 (t, 1 H,  $\text{CH}_{\text{Ph}}$ ,  $^3J = 7.4$  Hz); 7.28 (t, 2 H,  $\text{CH}_{\text{Ph}}$ ,  $^3J = 7.4$  Hz); 7.30–7.34 (m, 2 H,  $\text{CH}_{\text{Ph}}$ ); 7.39 (t, 1 H,  $\text{CH}_{\text{Ph}}$ ,  $^3J = 7.5$  Hz); 7.41 (d, 2 H,  $\text{CH}_{\text{Ph}}$ ,  $^3J = 7.6$  Hz); 7.65 (d, 2 H,  $\text{CH}_{\text{Ph}}$ ,  $^3J = 7.6$  Hz). MS,  $m/z$  ( $I_{\text{rel}}$  (%)): 413 [ $\text{M}]^+$  (100).

**Asymmetric allylic sulfonylation of (*E*)-1,3-diphenylallyl acetate (**3**) with sodium *p*-toluenesulfinate.** A solution of  $[\text{Pd}(\text{allyl})\text{Cl}]_2$  (0.0019 g, 0.005 mmol) and ligand **2** (0.004 g, 0.01 mmol or 0.008 g, 0.02 mmol) in THF (1.5 mL) was stirred for 40 min. Then (*E*)-1,3-diphenylallyl acetate (**3**) (0.05 mL, 0.25 mmol) was added. After 15 min stirring, sodium *p*-toluenesulfinate (0.089 g, 0.5 mmol) was added and stirring was continued for 48 h. To the reaction mixture, brine (3 mL) was added, the mixture was stirred for 1 h and extracted with THF (3×2 mL). The organic layer was washed with brine (2×2 mL), dried with  $\text{MgSO}_4$ , and filtered through Celite. The solvent was removed *in vacuo*

**Table 1.** Pd-catalyzed asymmetric allylic sulfonylation<sup>a</sup> of diphenylallyl acetate **3** with sodium *p*-toluenesulfinate in the presence of ligand **2**

Entry	Ratio ligand <b>2</b> : Pd (mol/mol)	Yield of <b>4</b> (%)	<i>ee</i> (%) <sup>b,c</sup>
1	1	87	90 ( <i>S</i> )
2	2	92	85 ( <i>S</i> )

<sup>a</sup> Reaction conditions:  $[\text{Pd}(\text{allyl})\text{Cl}]_2$  (2 mol.%), THF, 20 °C, 48 h.

<sup>b</sup> Enantiomeric excesses of product **4** were determined by HPLC (chiral column Daicel Chiralcel OD-H, elution with  $\text{C}_6\text{H}_{14}-\text{Pr}^i\text{OH}$  (4 : 1), eluent flow rate 0.5 mL min<sup>-1</sup>, detection at  $\lambda = 254$  nm, retention times  $t(R) = 16.3$  min,  $t(S) = 18.5$  min).

<sup>c</sup> Configuration of the product is given in parentheses.

(40 Torr). Crystallization of the residue from 95% EtOH followed by drying *in vacuo* (10 Torr) afforded product **4**, milk-white crystals. IR and NMR  $^1\text{H}$  spectral data for compound **4** are in good agreement with that published earlier.<sup>9</sup> Enantiomeric excesses of product **4** (see Table 1) were determined by HPLC on a chiral stationary phase.

This work was financially supported by the Russian Foundation for Basic Research (Project No. 11-03-00347-a).

### References

1. K. C. Bhowmick, N. N. Joshi, *Tetrahedron: Asymmetry*, 2006, **17**, 1901.
2. D. Seebach, A. K. Beck, A. Heckel, *Angew. Chem., Int. Ed.*, 2001, **40**, 92.
3. H. Pellissier, *Tetrahedron*, 2008, **64**, 10279.
4. M. D. K. Boele, P. C. J. Kamer, M. Lutz, A. L. Spek, J. G. de Vries, P. W. N. M. van Leeuwen, G. P. F. van Strijdonck, *Chem. — Eur. J.*, 2004, **10**, 6232.
5. R. Hilgraf, A. Pfaltz, *Adv. Synth. Catal.*, 2005, **347**, 61.
6. S. M. Smith, N. C. Thacker, J. M. Takacs, *J. Am. Chem. Soc.*, 2008, **130**, 3734.
7. C. A. Falcioni, A. Alexakis, *Eur. J. Org. Chem.*, 2008, 3765.
8. P. W. N. M. van Leeuwen, P. C. J. Kamer, C. Claver, O. Pamies, M. Diéguez, *Chem. Rev.*, 2011, **111**, 2077.
9. D. Seebach, E. Devaquet, A. Ernst, M. Hayakawa, F. N. M. Kiihnle, W. B. Schweizer, B. Weher, *Helv. Chim. Acta*, 1995, **78**, 1636.
10. Q.-L. Zhou, in *Privileged Chiral Ligands and Catalysts*, Ed. Q.-L. Zhou, Wiley-VCH, Weinheim, 2011, 484 pp.
11. K. V. L. Crepy, T. Imamoto, *Adv. Synth. Catal.*, 2003, **345**, 79.
12. P. R. Auburn, P. B. McKenzie, B. Bosnich, *J. Am. Chem. Soc.*, 1985, **107**, 2033.
13. V. N. Tsarev, S. E. Lyubimov, A. A. Shiryaev, S. V. Zheglov, O. G. Bondarev, V. A. Davankov, A. A. Kabro, S. K. Moiseev, V. N. Kalinin, K. N. Gavrilov, *Eur. J. Org. Chem.*, 2004, 2214.

Received June 3, 2013